Patents Assigned to Medicago Inc.
-
Patent number: 11884929Abstract: An expression enhancer comprising a CPMV 5?UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3? end of the 5?UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences.Type: GrantFiled: May 21, 2020Date of Patent: January 30, 2024Assignee: Medicago Inc.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11833200Abstract: Methods of preparing plant-derived proteins or suprastructure proteins, are provided. The method may comprise obtaining a plant, or plant matter comprising apoplast-localized proteins, or suprastructure proteins, producing a protoplast/spheroplast fraction and apoplast fraction from the plant or plant matter, and recovering the apoplast fraction. The apoplast fraction comprises plant-derived proteins or suprastructure proteins. Alternatively, the proteins, or suprastructure proteins, may be obtained from plant or plant matter comprising plant-derived proteins or suprastructure proteins, by digesting the plant matter using a cell wall degrading enzyme composition to produced a digested fraction. The digested fraction is filtered to produced a filtered fraction, and the plant-derived proteins or suprastructure proteins, are recovered from the filtered fraction.Type: GrantFiled: September 21, 2010Date of Patent: December 5, 2023Assignee: MEDICAGO INC.Inventors: Louis-Philippe Vezina, Manon Couture, Dany Paquet, Michele Dargis, Marc-Andre D'Aoust
-
Patent number: 11826419Abstract: Methods of preparing plant-derived virus like particles (VLPs) are provided. The method may comprise obtaining a plant, or plant matter comprising apoplast-localized VLPs, producing a protoplast/spheroplast fraction and apoplast fraction from the plant or plant matter, and recovering the apoplast fraction. The apoplast fraction comprises plant-derived VLPs. Alternatively, VLPs may be obtained from plant or plant matter comprising plant-derived VLPs by digesting the plant matter using a cell wall degrading enzyme composition to produced a digested fraction. The digested fraction is filtered to produced a filtered fraction, and the plant-derived VLPs are recovered from the filtered fraction.Type: GrantFiled: September 21, 2010Date of Patent: November 28, 2023Assignee: MEDICAGO INC.Inventors: Louis-Philippe Vezina, Manon Couture, Dany Paquet, Michele Dargis, Marc-Andre D'Aoust
-
Publication number: 20230293663Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and virus-like particles (VLPs) containing one or more of the modified norovirus VP1 proteins, and compositions containing the nucleic acids, VP1 proteins, or the VLPs are provided. Methods for producing modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also provided.Type: ApplicationFiled: February 7, 2023Publication date: September 21, 2023Applicant: MEDICAGO INC.Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Patent number: 11759512Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.Type: GrantFiled: November 30, 2018Date of Patent: September 19, 2023Assignee: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie
-
Patent number: 11608361Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.Type: GrantFiled: March 23, 2018Date of Patent: March 21, 2023Assignee: MEDICAGO INC.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11602558Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.Type: GrantFiled: November 30, 2018Date of Patent: March 14, 2023Assignee: MEDICAGO INC.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11576317Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: GrantFiled: November 13, 2020Date of Patent: February 14, 2023Assignees: CELLECTIS SA, MEDICAGO INC.Inventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
-
Publication number: 20230024533Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.Type: ApplicationFiled: May 3, 2022Publication date: January 26, 2023Applicant: MEDICAGO INC.Inventors: Pierre-Olivier LAVOIE, Marc-Andre D'AOUST
-
Patent number: 11555198Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.Type: GrantFiled: October 31, 2013Date of Patent: January 17, 2023Assignees: CELLECTIS SA, MEDICAGO INC.Inventors: Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
-
Patent number: 11441150Abstract: An expression enhancer comprising a CPMV 5?UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3? end of the 5?UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences. Plants comprising the expression enhancer and methods using the expression enhancer are also described.Type: GrantFiled: January 8, 2015Date of Patent: September 13, 2022Assignee: Medicago Inc.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11434497Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: December 13, 2018Date of Patent: September 6, 2022Assignee: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
-
Patent number: 11390878Abstract: A method of increasing the yield, stability, or both of an acid sensitive protein in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding the acid sensitive protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby increasing the yield of the acid sensitive protein when compared to the yield of the acid sensitive protein produced in the plant or portion of the plant produced under the same conditions, and in the absence of the proton channel protein.Type: GrantFiled: January 26, 2015Date of Patent: July 19, 2022Assignees: MEDICAGO INC., UNIVERSITE LAVALInventors: Marc-Andre D'Aoust, Manon Couture, Louis-Philippe Vezina, Dominique Michaud, Philippe Varennes-Jutras, Frank Sainsbury
-
Publication number: 20220145317Abstract: A method of producing a virus like particle (VLP) in a plant comprising modified H3 hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP. The virus like particle (VLP) may comprise plant-specific N-glycans, or modified N-glycans.Type: ApplicationFiled: August 6, 2021Publication date: May 12, 2022Applicant: MEDICAGO INC.Inventors: Manon COUTURE, Marc-Andre D'AOUST, Louis-Philippe VEZINA
-
Publication number: 20210393765Abstract: Nucleic acids encoding rotavirus VP7 fusion proteins and rotavirus-like particle (RLPs) comprising the rotavirus VP7 fusion proteins are provided. Methods for rotavirus VP7 fusion protein and RLP production in plants are also described. The VP7 fusion protein comprises a first sequence encoding a 7-1a subdomain, a second sequence encoding a 7-2 domain and a third sequence encoding a 7-1b subdomain; wherein the sequence of the 7-2 domain is derived from a first rotavirus strain and the sequence of the 7-1a subdomain, the sequence of the 7-1b subdomain or the sequence of the 7-1a subdomain and the sequence of the 7-1b subdomain are derived from a second rotavirus strain.Type: ApplicationFiled: February 19, 2020Publication date: December 23, 2021Applicants: MEDICAGO INC., MITSUBISHI TANABE PHARMA CORPORATIONInventors: Marc-Andre D AOUST, Pierre-Olivier LAVOIE
-
Patent number: 11155581Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.Type: GrantFiled: September 28, 2012Date of Patent: October 26, 2021Assignee: MEDICAGO INC.Inventors: Marc-Andre D'aoust, Manon Couture, Louis-Philippe Vezina
-
Publication number: 20210246462Abstract: An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbMT78 (SEQ ID NO:1); nbATL75 (SEQ ID NO:2); nbDJ46 (SEQ ID NO:3); nbCHP79 (SEQ ID NO:4); nbEN42 (SEQ ID NO:5); atHSP69 (SEQ ID NO:6); atGRP62 (SEQ ID NO:7); atPK65 (SEQ ID NO:8); atRP46 (SEQ ID NO:9); nb30S72 (SEQ ID NO:10); nbGT61 (SEQ ID NO:11); nbPV55 (SEQ ID NO:12); nbPPI43 (SEQ ID NO:13); nbPM64 (SEQ ID NO:14); and nbH2A86 (SEQ ID NO:15). Methods for using the isolated expression enhancer are also provided.Type: ApplicationFiled: March 14, 2019Publication date: August 12, 2021Applicants: Medicago Inc., National University Corporation Nara Institute of Science and Technology, Mitsubishi TanabePhatmaCorporationInventors: Pierre-Oliver LAVOIE, Marc-Andre D'AOUST, Ko KATO, Shotaro YAMASAKI
-
Patent number: 11085049Abstract: A method of producing a virus like particle (VLP) in a plant comprising modified hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. The nucleotide sequence encoding the HA may be selected from the group consisting of B HA, C, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP.Type: GrantFiled: July 19, 2019Date of Patent: August 10, 2021Assignee: MEDICAGO INC.Inventors: Manon Couture, Marc-Andre D'Aoust, Louis-Philippe Vezina
-
Publication number: 20210128714Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.Type: ApplicationFiled: November 30, 2018Publication date: May 6, 2021Applicant: MEDICAGO INC.Inventors: Marc-Andre D'AOUST, Pierre-Olivier LAVOIE
-
Patent number: 10907168Abstract: A method of increasing expression of an heterologous protein of interest in a plant or portion of the plant is provided. The method comprises treating the plant or portion of the plant with a jasmonate-pathway activator, and introducing a nucleotide sequence operably linked to a regulatory region derived from a DNA plant virus and encoding the heterologous protein of interest into the plant or portion of the plant. Alternatively, the plant or plant portion may comprise the nucleic acid and encoding the heterologous protein of interest, and the plant or portion of the plant is treated with the jasmonate pathway activator. The treated plant is incubated under conditions to permit expression of the nucleotide sequence encoding the heterologous protein of interest.Type: GrantFiled: June 30, 2016Date of Patent: February 2, 2021Assignees: MEDICAGO INC., UNIVERSITE LAVALInventors: Marc-Andre D'Aoust, Stephanie Robert, Marie-Claire Goulet, Dominique Michaud, Frank Sainsbury